Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 10/20 | 0.61 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.59 |
| ▸ | CCKBR | P32239 | 1/20 | 0.56 |
| ▸ | EDNRA | P25101 | 1/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 2/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30311133 | 0.92 | KISS1R (0.58) | CXCL8KISS1RCCKBR | |
| SCHEMBL30511828 | 0.85 | NPY1R (0.61) | CXCL8KISS1RCCKBRNPY1RNPY2R | |
| SCHEMBL31083911 | 0.85 | CXCL8 (0.64) | CXCL8KISS1RCCKBR | |
| SCHEMBL29716758 | 0.84 | CXCR4 (0.60) | CCKBRNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31083903 | 0.84 | F13A1 (0.52) | KISS1RCCKBREDNRANTSR2NTSR1 | |
| SCHEMBL31606506 | 0.84 | KISS1R (0.61) | CXCL8KISS1RCCKBRNTSR2NTSR1 | |
| SCHEMBL30600981 | 0.83 | NPY1R (0.60) | CXCL8KISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL21955405 | 0.83 | IL23R (0.64) | CXCL8KISS1RCCKBR | |
| SCHEMBL31679385 | 0.83 | NTSR1 (0.60) | NTSR2NTSR1 | |
| SCHEMBL30310961 | 0.83 | CXCL8 (0.61) | CXCL8KISS1RCCKBRNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| CN-118632858-A | Gastric inhibitory peptide receptor ligands | 3B制药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4423110-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | CXCL8 1597/4885KISS1R 91/4885CCKBR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.